A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Completed · Phase 3

Conditions studied: Atopic Dermatitis

In brief

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.

Key facts

Study ID: NCT05372419
Run by: Eli Lilly and Company
People needed: 90
Starts: 2023-01-12
Expected to finish: 2025-02-17
Last updated by the study team: 2026-03-09

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participants must be ≥12 years of age inclusive, at the time of signing the informed consent/assent.
Participants who are self-reported race other than White, including but not limited to persons who self-identify as Black or African American, American Indian or Alaska Native, Asian, Native Hawaiian, or Other Pacific Islander.
Participants who are Fitzpatrick phototype IV-VI
Participants who have chronic AD that has been present for ≥1 year before screening.
Have EASI ≥16 at baseline
Have IGA score ≥3 (Scale of 0 to 4) at baseline
Have ≥10% body surface area (BSA) of AD involvement at baseline
Have a history of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.
Adolescents body weight must be ≥40 kg at baseline.
Are willing and able to comply with all clinic visits and study-related procedures and questionnaires.
Contraceptive use - Male and/or female
Male participants are not required to use any contraception except in compliance with specific local government study requirements.
Female participants of child-bearing potential: must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 18 weeks after the last dose of study drug. Women of non-child-bearing potential (non-WOCBP) may participate without any contraception requirements.

You may not qualify if…

History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.
Have a current infection or chronic infection with hepatitis B virus (HBV) at screening, that is, positive for hepatitis B surface antigen (HBsAg) and/or polymerase chain reaction positive for HBV DNA
Have a current infection with hepatitis C virus (HCV) at screening, that is, positive for HCV RNA
Have an uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids at screening (as defined by the investigator).
Have uncontrolled asthma that
might require bursts of oral or systemic corticosteroids, or
required the following due to ≥1 exacerbations within 12 months before baseline
systemic (oral and/or parenteral) corticosteroid treatment, or
hospitalization for >24 hours.
Have known liver cirrhosis and/or chronic hepatitis of any etiology.
Had prior treatment with dupilumab
Had prior treatment with tralokinumab
Treatment with topical agents (corticosteroids, calcineurin inhibitors, JAK inhibitors, or phosphodiesterase-4 inhibitors) within 2 weeks prior to baseline.
Treatment with any of the following agents within 4 weeks prior to the baseline:
systemic immunosuppressive/immunomodulating drugs (for example, systemic corticosteroids, cyclosporine, mycophenolate mofetil, IFN-gamma, azathioprine, methotrexate, and other immunosuppressants);
small molecules (for example, Janus Kinase (JAK) inhibitors);
phototherapy and photochemotherapy for AD.
History of malignancy, including mycosis fungoides or cutaneous T-cell lymphoma, within 5 years before the screening, except completely treated in situ carcinoma of the cervix of completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks.

Where it is running

Total Skin and Beauty Dermatology Center, PC — Birmingham, Alabama, United States
First OC Dermatology — Fountain Valley, California, United States
Center For Dermatology Clinical Research, Inc. — Fremont, California, United States
Axon Clinical Research — Inglewood, California, United States
Avance Clinical Trials Inc — Laguna Niguel, California, United States
Dermatology Research Associates — Los Angeles, California, United States
Wallace Medical Group, Inc. — Los Angeles, California, United States
Cura Clinical Research — Palmdale, California, United States
University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California, United States
Clinical Science Institute — Santa Monica, California, United States
Cura Clinical Research — Sherman Oaks, California, United States
UConn Health — Farmington, Connecticut, United States
Encore Medical Research of Boynton Beach — Boynton Beach, Florida, United States
Skin Care Research, Inc — Hollywood, Florida, United States
Solutions Through Advanced Research — Jacksonville, Florida, United States
Miami Dermatology and Laser Research — Miami, Florida, United States
Savin Medical Group, LLC — Miami Lakes, Florida, United States
PureSkin Dermatology — Orlando, Florida, United States
Skin Care Physicians of Georgia — Macon, Georgia, United States
Advanced Medical Research — Sandy Springs, Georgia, United States
Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
Allcutis Research, Inc. — Beverly, Massachusetts, United States
Oakland Hills Dermatology — Auburn Hills, Michigan, United States
Revival Research Institute - Troy — Troy, Michigan, United States
Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.